Revenue and profit at Integrated Diagnostics just moved again, with the Q2 2026 report showing higher sales and earnings but a thinner net margin than a year earlier. Holding Integrated Diagnostics from the start of the year would have meant a 21.6% loss, including dividends. If you had made that call on 1 January, how much of this outcome lines up with what was already on record, and what now deserves a closer look?
If the move has made Integrated Diagnostics harder to judge, start where the gap is still open and scan 9 high quality undervalued stocks.
The Two Integrated Diagnostics Stories Investors Had To Weigh
The shares cost US$0.74 at the start of the period, and anyone looking at Integrated Diagnostics then was really choosing between two grounded stories that pointed in different directions.
The bullish camp argued that digital and house-call services could reshape MENA diagnostics. It treated a Fair Value of US$0.91, a price implied by those growth assumptions, as reasonable if scale gains and margin expansion played out. That view leaned on higher average revenue per patient and broader test menus through advanced diagnostics.
The more cautious narrative worked off a Fair Value of US$0.68 and focused on execution risk. It accepted that acquisitions and new branches in Saudi Arabia and Egypt might lift earnings, but worried that economic instability and currency pressure in core markets could blunt those benefits.
What The Results Changed For Integrated Diagnostics
The clearest new fact was operational. Integrated Diagnostics reported Q2 2026 revenue of EGP 2,783.406m and net income of EGP 384.535m, both above Q2 2025, while net margin slipped from 15.6% to 13.8%. Higher sales and earnings backed the optimistic story on demand, but the thinner profitability supported the cautious view on execution. The period cut both ways.
The lesson is simple. When a thesis leans on margin expansion, you need to track net income and net margin together, quarter by quarter, rather than relying on revenue alone.
What Integrated Diagnostics' Lower Price Now Asks You To Believe
Integrated Diagnostics now trades at US$0.55, after a share price that declined 21.6% from the start of the year. The selected Narrative still places its Fair Value above that level, based on how repricing, new branches and Saudi acquisitions might affect earnings power as operations mature.
You now have to decide whether that fall is a warning about macro and execution risks, or an opening if you think branch expansion, repricing and Saudi growth can outweigh those pressures over time.
"IDH surprised the market by achieving record-high revenue growth of 39% year-on-year, partly due to increased test volumes and strategic repricing to counteract inflation, which is likely to drive future revenue expansion and support higher earnings."
The price and this Narrative do not agree. → Uncover what this Narrative says Integrated Diagnostics is actually worth
Looking Beyond Integrated Diagnostics
Integrated Diagnostics gives you exposure to testing demand, but it is not the only diagnostics angle.
Hospitals and clinics still need accurate tools that run inside their own labs.
That means reliable systems to process blood work, screen for infections and check critical markers.
Another global player focuses on that side of healthcare, building devices and tests that help clinicians track chronic conditions and monitor treatment.
If you are weighing diagnostics risk through Integrated Diagnostics alone, that parallel route might deserve a closer look.
That argument has a Narrative and a number behind it. → See the company one Narrative values 23% above its price
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com